This study is in progress, not accepting new patients
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Summary
- Eligibility
- for males ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
- Principal Investigator
- by Allan Pantuck (ucla)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Allan Pantuck (ucla)
Department Vice Chair, Urology, Medicine. Authored (or co-authored) 262 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Aragon Pharmaceuticals, Inc.
- ID
- NCT02257736
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 982 people participating
- Last Updated